PH12020550239A1 - Periodontitis vaccine and related compositions and methods of use - Google Patents

Periodontitis vaccine and related compositions and methods of use

Info

Publication number
PH12020550239A1
PH12020550239A1 PH12020550239A PH12020550239A PH12020550239A1 PH 12020550239 A1 PH12020550239 A1 PH 12020550239A1 PH 12020550239 A PH12020550239 A PH 12020550239A PH 12020550239 A PH12020550239 A PH 12020550239A PH 12020550239 A1 PH12020550239 A1 PH 12020550239A1
Authority
PH
Philippines
Prior art keywords
antigen sequence
rgpa
sequence
gingipain
methods
Prior art date
Application number
PH12020550239A
Other languages
English (en)
Inventor
Jeffery Fairman
Original Assignee
Vaxcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxcyte Inc filed Critical Vaxcyte Inc
Publication of PH12020550239A1 publication Critical patent/PH12020550239A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0216Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PH12020550239A 2017-10-12 2020-04-08 Periodontitis vaccine and related compositions and methods of use PH12020550239A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762571582P 2017-10-12 2017-10-12
PCT/US2018/055496 WO2019075260A1 (en) 2017-10-12 2018-10-11 VACCINE AGAINST PERIODONTITIS AND ASSOCIATED COMPOSITIONS AND METHOD OF USE

Publications (1)

Publication Number Publication Date
PH12020550239A1 true PH12020550239A1 (en) 2021-02-15

Family

ID=64110091

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020550239A PH12020550239A1 (en) 2017-10-12 2020-04-08 Periodontitis vaccine and related compositions and methods of use

Country Status (14)

Country Link
US (3) US10835590B2 (enExample)
EP (1) EP3694547A1 (enExample)
JP (2) JP7258870B2 (enExample)
KR (2) KR102530966B1 (enExample)
CN (1) CN111225684A (enExample)
AU (1) AU2018347511A1 (enExample)
CA (1) CA3078630A1 (enExample)
EA (1) EA202090908A1 (enExample)
IL (1) IL273690A (enExample)
MA (1) MA50363A (enExample)
MX (1) MX2020003810A (enExample)
PH (1) PH12020550239A1 (enExample)
SG (1) SG11202003147XA (enExample)
WO (1) WO2019075260A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202090908A1 (ru) * 2017-10-12 2020-10-29 Ваксайт, Инк. Вакцина и связанные композиции для лечения пародонтита и способ применения
WO2025019900A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Chimeric protein vaccine
CN116751292B (zh) * 2023-07-31 2024-05-14 河南大学 牙龈卟啉单胞菌Mfa1单克隆抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128338A (ja) 1982-12-08 1984-07-24 Kitasato Inst:The 歯周炎予防用ワクチン及びその製法
FI955720A0 (fi) 1993-05-28 1995-11-27 Chiron Corp Urokinaasireseptoriaktiivisuuden peptidi-inhibiittoreita
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
JP2000507245A (ja) 1996-03-22 2000-06-13 ユニバーシティー オブ ジョージア リサーチ ファウンデーション,インコーポレイテッド Porphyromonas gingivalisペプチドを含む免疫原性組成物および方法
US6833262B1 (en) 1999-04-21 2004-12-21 University Of Georgia Research Foundation, Inc. Polypeptide having amidolytic activity for a serpin
AUPQ065299A0 (en) 1999-05-28 1999-06-24 University Of Sydney, The A method of prophylaxis and treatment and agents useful for same
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
US7378101B2 (en) 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
GB0411150D0 (en) 2004-05-19 2004-06-23 Queen Mary & Westfield College Vaccine
US9366673B2 (en) 2009-08-02 2016-06-14 Sanofi Pasteur Limited Porphyromonas gingivalis polypeptides
EP2533794A4 (en) 2010-02-12 2014-04-23 Univ Sydney PROTEINDOMAINS AND USES THEREOF
US9040253B2 (en) 2010-04-14 2015-05-26 Sutro Biopharma, Inc. Method for enhancing recombinant protein production by cell-free protein expression system
AU2013329464C1 (en) 2012-10-12 2018-02-15 Sutro Biopharma, Inc. Proteolytic inactivation of select proteins in bacterial extracts for improved expression
WO2017066719A2 (en) * 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
EA202090908A1 (ru) 2017-10-12 2020-10-29 Ваксайт, Инк. Вакцина и связанные композиции для лечения пародонтита и способ применения

Also Published As

Publication number Publication date
KR20200070302A (ko) 2020-06-17
US12121575B2 (en) 2024-10-22
JP7258870B2 (ja) 2023-04-17
KR102530966B1 (ko) 2023-05-15
EP3694547A1 (en) 2020-08-19
WO2019075260A1 (en) 2019-04-18
KR20230066660A (ko) 2023-05-16
CN111225684A (zh) 2020-06-02
BR112020006500A2 (pt) 2020-10-13
US20210361756A1 (en) 2021-11-25
US11701414B2 (en) 2023-07-18
CA3078630A1 (en) 2019-04-18
US20240131134A1 (en) 2024-04-25
MA50363A (fr) 2020-08-19
US20190192645A1 (en) 2019-06-27
MX2020003810A (es) 2020-08-13
US10835590B2 (en) 2020-11-17
EA202090908A1 (ru) 2020-10-29
SG11202003147XA (en) 2020-05-28
JP2023098935A (ja) 2023-07-11
JP2020536925A (ja) 2020-12-17
AU2018347511A8 (en) 2020-06-11
AU2018347511A1 (en) 2020-05-21
IL273690A (en) 2020-05-31
US20240226259A9 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
PH12020550239A1 (en) Periodontitis vaccine and related compositions and methods of use
CY1119436T1 (el) Σκευασμα για αντισωμα εναντι- 4 7
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
IN2014KN01715A (enExample)
EA201692315A1 (ru) Составы и способы обработки кератина
MX2018014631A (es) Formulacion de neurotoxina.
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MA40151A1 (fr) Vaccins de recombinaison fmdv et leurs utilisations
CL2018003178A1 (es) Composición farmacéutica
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
EA201991065A1 (ru) Вакцина против свиного парвовируса
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
ZA202102816B (en) High concentration protein formulation
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
WO2013171661A3 (en) Adjuvant formulations and methods
JP2020536925A5 (enExample)
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo
MX2021015732A (es) Administracion intranasal de merotocina para mejorar la lactancia.
EA202290122A1 (ru) Фармацевтические композиции в форме геля, содержащие ксилоглюкан и спирты, для регулируемого высвобождения активных ингредиентов
MX2022009549A (es) Tratamiento que implica vacunacion con antigeno y agentes de union que se unen a pd-l1 y cd137.
AR083006A1 (es) Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CO2024012167A2 (es) Formulaciones estables para anticuerpos